Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 8 | 2022 | 543 | 1.630 |
Why?
|
| Text Messaging | 2 | 2022 | 25 | 1.310 |
Why?
|
| Stavudine | 3 | 2013 | 78 | 1.080 |
Why?
|
| HIV Infections | 21 | 2022 | 5097 | 1.080 |
Why?
|
| Anti-HIV Agents | 6 | 2021 | 1324 | 1.050 |
Why?
|
| Humans | 38 | 2022 | 14537 | 0.820 |
Why?
|
| Adult | 24 | 2022 | 5913 | 0.790 |
Why?
|
| South Africa | 29 | 2022 | 7596 | 0.780 |
Why?
|
| Male | 25 | 2022 | 6754 | 0.780 |
Why?
|
| Adenine | 2 | 2013 | 91 | 0.740 |
Why?
|
| Antitubercular Agents | 3 | 2021 | 322 | 0.700 |
Why?
|
| Female | 25 | 2022 | 9103 | 0.680 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2021 | 12 | 0.680 |
Why?
|
| Students, Medical | 1 | 2020 | 14 | 0.650 |
Why?
|
| Liver Cirrhosis | 1 | 2020 | 28 | 0.640 |
Why?
|
| Lost to Follow-Up | 2 | 2020 | 62 | 0.640 |
Why?
|
| Hepacivirus | 1 | 2020 | 37 | 0.640 |
Why?
|
| Hepatitis C, Chronic | 1 | 2020 | 26 | 0.640 |
Why?
|
| Allied Health Personnel | 1 | 2020 | 6 | 0.640 |
Why?
|
| Community-Institutional Relations | 1 | 2019 | 6 | 0.620 |
Why?
|
| Neurocysticercosis | 1 | 2019 | 3 | 0.610 |
Why?
|
| Retrospective Studies | 8 | 2022 | 799 | 0.610 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 37 | 0.600 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 61 | 0.600 |
Why?
|
| Malaria | 1 | 2021 | 213 | 0.590 |
Why?
|
| Middle Aged | 14 | 2022 | 3601 | 0.590 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 106 | 0.580 |
Why?
|
| Coinfection | 3 | 2019 | 276 | 0.550 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2013 | 472 | 0.480 |
Why?
|
| Echinococcosis | 5 | 2013 | 6 | 0.470 |
Why?
|
| Wound Infection | 1 | 2015 | 2 | 0.450 |
Why?
|
| Drug Resistance, Microbial | 1 | 2015 | 26 | 0.450 |
Why?
|
| Burns | 1 | 2015 | 12 | 0.450 |
Why?
|
| Phosphorous Acids | 1 | 2013 | 14 | 0.400 |
Why?
|
| Health Services Accessibility | 4 | 2020 | 280 | 0.400 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2013 | 8 | 0.390 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2013 | 8 | 0.390 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2013 | 6 | 0.390 |
Why?
|
| Bacteriological Techniques | 1 | 2013 | 54 | 0.380 |
Why?
|
| Adipocytes | 1 | 2012 | 23 | 0.370 |
Why?
|
| Organophosphonates | 1 | 2012 | 45 | 0.370 |
Why?
|
| Risk Factors | 6 | 2021 | 1475 | 0.370 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2012 | 118 | 0.360 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2013 | 132 | 0.360 |
Why?
|
| Aged | 6 | 2022 | 1740 | 0.350 |
Why?
|
| Meningitis, Cryptococcal | 2 | 2022 | 16 | 0.340 |
Why?
|
| Prospective Studies | 5 | 2021 | 1160 | 0.330 |
Why?
|
| Tertiary Care Centers | 2 | 2021 | 80 | 0.320 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 253 | 0.320 |
Why?
|
| Meningitis, Bacterial | 2 | 2022 | 38 | 0.250 |
Why?
|
| Genotype | 2 | 2020 | 442 | 0.230 |
Why?
|
| Cryptococcosis | 2 | 2022 | 17 | 0.220 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2020 | 195 | 0.210 |
Why?
|
| Hospital Mortality | 2 | 2022 | 95 | 0.210 |
Why?
|
| Flucytosine | 2 | 2022 | 4 | 0.200 |
Why?
|
| Antifungal Agents | 2 | 2022 | 40 | 0.200 |
Why?
|
| Comorbidity | 2 | 2022 | 188 | 0.200 |
Why?
|
| DNA, Mitochondrial | 2 | 2013 | 31 | 0.190 |
Why?
|
| Glucose | 2 | 2013 | 45 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 125 | 0.190 |
Why?
|
| Lipid Metabolism | 2 | 2013 | 44 | 0.190 |
Why?
|
| Prevalence | 6 | 2021 | 1192 | 0.190 |
Why?
|
| Inflammation | 2 | 2013 | 104 | 0.180 |
Why?
|
| Meningitis, Meningococcal | 1 | 2022 | 17 | 0.180 |
Why?
|
| ROC Curve | 2 | 2020 | 51 | 0.180 |
Why?
|
| Meningitis, Pneumococcal | 1 | 2022 | 20 | 0.180 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 370 | 0.180 |
Why?
|
| Platelet Count | 2 | 2020 | 14 | 0.180 |
Why?
|
| Technology | 1 | 2022 | 4 | 0.180 |
Why?
|
| Neisseria meningitidis | 1 | 2022 | 36 | 0.180 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2022 | 4 | 0.180 |
Why?
|
| Biomarkers | 2 | 2013 | 327 | 0.180 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 2 | 2013 | 20 | 0.180 |
Why?
|
| Leprosy | 1 | 2021 | 3 | 0.170 |
Why?
|
| Travel | 1 | 2021 | 21 | 0.170 |
Why?
|
| Health Personnel | 2 | 2021 | 231 | 0.170 |
Why?
|
| Moral Obligations | 1 | 2020 | 1 | 0.170 |
Why?
|
| Patient Rights | 1 | 2020 | 3 | 0.170 |
Why?
|
| Lamivudine | 2 | 2013 | 89 | 0.170 |
Why?
|
| Morals | 1 | 2020 | 5 | 0.170 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 10 | 0.160 |
Why?
|
| Area Under Curve | 1 | 2020 | 20 | 0.160 |
Why?
|
| Ribavirin | 1 | 2020 | 15 | 0.160 |
Why?
|
| Interferon-alpha | 1 | 2020 | 15 | 0.160 |
Why?
|
| Sustained Virologic Response | 1 | 2020 | 22 | 0.160 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 49 | 0.160 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 73 | 0.160 |
Why?
|
| Invasive Fungal Infections | 1 | 2020 | 2 | 0.160 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 146 | 0.160 |
Why?
|
| Sample Size | 1 | 2019 | 4 | 0.150 |
Why?
|
| Program Evaluation | 1 | 2020 | 89 | 0.150 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 279 | 0.150 |
Why?
|
| Antiviral Agents | 1 | 2020 | 111 | 0.150 |
Why?
|
| Pandemics | 1 | 2022 | 296 | 0.150 |
Why?
|
| Social Stigma | 1 | 2020 | 80 | 0.150 |
Why?
|
| Biopsy | 1 | 2019 | 38 | 0.150 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 1422 | 0.150 |
Why?
|
| Counseling | 1 | 2020 | 143 | 0.150 |
Why?
|
| Kidney | 1 | 2019 | 46 | 0.150 |
Why?
|
| Kidney Diseases | 1 | 2019 | 38 | 0.150 |
Why?
|
| Referral and Consultation | 3 | 2013 | 57 | 0.140 |
Why?
|
| Hospitalization | 1 | 2021 | 418 | 0.140 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2013 | 324 | 0.130 |
Why?
|
| Hypertension | 1 | 2022 | 419 | 0.130 |
Why?
|
| Echinococcus | 2 | 2013 | 5 | 0.120 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 435 | 0.120 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 163 | 0.120 |
Why?
|
| Adolescent | 4 | 2021 | 2985 | 0.120 |
Why?
|
| Young Adult | 4 | 2019 | 2498 | 0.120 |
Why?
|
| Incidence | 2 | 2015 | 685 | 0.120 |
Why?
|
| Burn Units | 1 | 2015 | 5 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 2 | 2015 | 293 | 0.110 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 385 | 0.110 |
Why?
|
| Bacteremia | 1 | 2015 | 79 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2015 | 66 | 0.110 |
Why?
|
| Surveys and Questionnaires | 2 | 2013 | 563 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2013 | 64 | 0.100 |
Why?
|
| Drug Substitution | 1 | 2013 | 33 | 0.100 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 2 | 2013 | 226 | 0.100 |
Why?
|
| Alkynes | 1 | 2013 | 117 | 0.100 |
Why?
|
| Cyclopropanes | 1 | 2013 | 123 | 0.100 |
Why?
|
| Anthropometry | 1 | 2013 | 102 | 0.100 |
Why?
|
| Patient Care | 1 | 2013 | 10 | 0.100 |
Why?
|
| Hospitals, Urban | 1 | 2013 | 23 | 0.100 |
Why?
|
| Benzoxazines | 1 | 2013 | 123 | 0.100 |
Why?
|
| HIV | 2 | 2012 | 380 | 0.100 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 57 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 41 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 22 | 0.090 |
Why?
|
| Body Composition | 1 | 2013 | 153 | 0.090 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2011 | 1 | 0.090 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2011 | 1 | 0.090 |
Why?
|
| Triage | 1 | 2011 | 11 | 0.090 |
Why?
|
| Time Factors | 1 | 2013 | 507 | 0.090 |
Why?
|
| Tenofovir | 1 | 2012 | 171 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 151 | 0.090 |
Why?
|
| Zoonoses | 1 | 2011 | 4 | 0.090 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2011 | 6 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2012 | 303 | 0.080 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 30 | 0.080 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2008 | 1 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2013 | 889 | 0.070 |
Why?
|
| Acinetobacter Infections | 1 | 2008 | 4 | 0.070 |
Why?
|
| Acinetobacter baumannii | 1 | 2008 | 11 | 0.070 |
Why?
|
| Anticestodal Agents | 1 | 2007 | 1 | 0.070 |
Why?
|
| Cestode Infections | 1 | 2007 | 1 | 0.070 |
Why?
|
| Gardening | 1 | 2007 | 2 | 0.070 |
Why?
|
| Albendazole | 1 | 2007 | 3 | 0.070 |
Why?
|
| Treatment Refusal | 1 | 2007 | 13 | 0.070 |
Why?
|
| Occupational Exposure | 1 | 2007 | 35 | 0.060 |
Why?
|
| Animals | 3 | 2013 | 1081 | 0.060 |
Why?
|
| Anti-Retroviral Agents | 1 | 2007 | 551 | 0.050 |
Why?
|
| Fluconazole | 1 | 2022 | 17 | 0.050 |
Why?
|
| Haemophilus influenzae | 1 | 2022 | 42 | 0.050 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2022 | 8 | 0.050 |
Why?
|
| Hospitals | 2 | 2013 | 103 | 0.040 |
Why?
|
| Child | 2 | 2021 | 2242 | 0.040 |
Why?
|
| Disease Progression | 1 | 2022 | 154 | 0.040 |
Why?
|
| Length of Stay | 1 | 2022 | 43 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2022 | 90 | 0.040 |
Why?
|
| Autopsy | 1 | 2022 | 140 | 0.040 |
Why?
|
| Africa South of the Sahara | 2 | 2012 | 353 | 0.040 |
Why?
|
| Primary Health Care | 2 | 2013 | 240 | 0.040 |
Why?
|
| Histoplasmosis | 1 | 2020 | 1 | 0.040 |
Why?
|
| Antigens, Fungal | 1 | 2020 | 9 | 0.040 |
Why?
|
| Inpatients | 1 | 2020 | 30 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2020 | 37 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2022 | 336 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 91 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2021 | 967 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2012 | 656 | 0.030 |
Why?
|
| Infant | 1 | 2022 | 2244 | 0.030 |
Why?
|
| Cattle | 1 | 2013 | 28 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 34 | 0.020 |
Why?
|
| Species Specificity | 1 | 2013 | 49 | 0.020 |
Why?
|
| Echinococcus granulosus | 1 | 2012 | 1 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2013 | 175 | 0.020 |
Why?
|
| Demography | 1 | 2013 | 105 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 254 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 468 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 370 | 0.020 |
Why?
|
| Neglected Diseases | 1 | 2011 | 1 | 0.020 |
Why?
|
| Livestock | 1 | 2011 | 1 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 106 | 0.020 |
Why?
|
| Survival Rate | 1 | 2010 | 96 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2010 | 198 | 0.020 |
Why?
|
| Viral Load | 1 | 2013 | 819 | 0.020 |
Why?
|
| Hematocrit | 1 | 2008 | 6 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2008 | 24 | 0.020 |
Why?
|
| Thienamycins | 1 | 2008 | 6 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2008 | 13 | 0.020 |
Why?
|
| Ceftriaxone | 1 | 2008 | 13 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 39 | 0.020 |
Why?
|
| Hemoptysis | 1 | 2007 | 4 | 0.020 |
Why?
|
| Cross Infection | 1 | 2008 | 52 | 0.020 |
Why?
|
| Hospitals, County | 1 | 2007 | 2 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2007 | 37 | 0.020 |
Why?
|
| Poverty Areas | 1 | 2007 | 20 | 0.020 |
Why?
|
| Community-Acquired Infections | 1 | 2008 | 102 | 0.020 |
Why?
|
| Sex Factors | 1 | 2007 | 227 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2007 | 411 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 2007 | 265 | 0.010 |
Why?
|
| Urban Population | 1 | 2007 | 257 | 0.010 |
Why?
|